Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel
Comprehensive genetic test evaluating key genes linked to inherited arrhythmias and cardiomyopathies. Helps clarify diagnosis, guide management, and assess familial risk.
Accessed through the Mission: Genome Sponsored Testing Program•Sponsored by Rocket Pharma•Performed by Invitae | Labcorp
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
The Mission: Genome Danon Disease Program, sponsored by Rocket Pharma and performed by Invitae (Labcorp), provides no-cost NGS-based genetic testing for US patients with clinical suspicion of Danon disease. Testing is delivered through the Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel, a 100-gene panel that includes LAMP2 alongside a broad set of cardiomyopathy and arrhythmia-associated genes. Eligible patients also receive no-cost post-test genetic counseling, and participation carries no obligation to recommend, prescribe, or use any product from Invitae, Rocket Pharma, or any third party.
When to consider this test
Patient selection
- To qualify, all of the following must be met:
- Resides in the United States
- Suspected of having a familial cardiomyopathy or arrhythmia — at least one of the following:
- Suspicion or known diagnosis of a familial cardiomyopathy or arrhythmia (e.g. HCM, DCM, ARVC, LVNC, LQTS, CPVT, BrS)
- Family history of a primary cardiomyopathy or arrhythmia
- Family history of unexplained sudden cardiac death
- Ordered by a qualified healthcare provider
Workflow
How to use this program
- 1
Submit an order
Place the order online or via paper TRF. Include the patient’s insurance information for benefits investigation.
- 2
Collect specimen
Collect a blood, buccal, or saliva specimen using a Labcorp kit and follow standard collection procedures.
- 3
Receive results
Turnaround time is typically 10–21 days from specimen receipt. Results will be available through your Labcorp portal.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Invitae | Labcorp, a CLIA-certified laboratory (CLIA 05D2040778). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which patients are appropriate for the Mission: Genome Danon Disease genetic testing program?
The Mission: Genome Danon Disease Program is available to US-based patients with clinical suspicion of Danon disease who meet the program's eligibility criteria. Healthcare professionals must confirm that patients satisfy these criteria before ordering. The broad 100-gene panel also enables identification of other arrhythmia and cardiomyopathy-related variants, which may be clinically relevant in the differential workup.
What does the Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel cover under the Mission: Genome Danon Disease Program?
The panel evaluates 100 genes associated with arrhythmias and cardiomyopathies using next-generation sequencing, with LAMP2 included as the primary gene of interest for Danon disease. Results are reported by Invitae (Labcorp). Eligible patients also have access to no-cost post-test genetic counseling to support result interpretation and clinical follow-up planning.
What specimen types and turnaround time apply to the Mission: Genome Danon Disease Program?
The Mission: Genome Danon Disease Program accepts whole blood, saliva, buccal swab, or extracted gDNA. Turnaround time is 10 to 21 days from specimen receipt. These options provide flexibility for both inpatient and outpatient collection workflows.
Is there any prescribing or purchase obligation when ordering through the Mission: Genome Danon Disease Program?
There is no obligation whatsoever. Healthcare professionals and patients who participate in the Mission: Genome Danon Disease Program, sponsored by Rocket Pharma, have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any products or services from Invitae, Rocket Pharma, or any other third party. The cost of testing and post-test genetic counseling is fully covered by the program sponsor.
Does the Mission: Genome Danon Disease Program include genetic counseling support?
Yes, eligible patients receive no-cost post-test genetic counseling through the Mission: Genome Danon Disease Program. This service supports result interpretation and helps guide clinical follow-up decisions. Counseling is included as part of the sponsored program at no charge to the patient or the ordering clinician.
Which patients are eligible for Mission: Genome Danon Disease genetic testing?
Patients may qualify for Mission: Genome if they meet the program's eligibility criteria:
- Patient must reside in the United States.
- Patient is 40 years of age or younger
- Provider has a high clinical suspicion for an inherited cardiomyopathy
- Patient meets at least one of the following:
- Documented family history of Danon disease
- Cardiomyopathy diagnosis not attributable to acquired etiologies (e.g., medications, viral myocarditis)
See an issue with this program?